

AMENDMENTS TO THE CLAIMS

Please cancel claims 60-65, 67, 68, 74, 75, and 293 without prejudice, amend claims 51 and 66, and add claims 294-313, as follows.

Claims 1-50 (Canceled)

Claim 51 (**Currently amended**): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of ~~a an isolated or recombinantly expressed polypeptide, wherein the amino acid sequence of said polypeptide consists essentially of: AVL₄SAX₄X₅LR (SEQ ID NO:1), wherein X₄ is D or E, X₅ is K or Q, and said polypeptide is free of at least one component naturally occurring with HSP47, comprising the an amino acid sequence AVL₄SAEQLR (SEQ ID NO:3), wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.~~

Claim 52-65 (Canceled)

Claim 66 (**Currently amended**): ~~The method of claim 51, wherein the amino acid sequence of said A method for protecting cells, organs or tissues comprising exposing said cells, organs or tissues to an immunoprotective amount of an isolated or recombinantly expressed Hsp47-polypeptide consists essentially of: comprising the sequence AVL₄SAEQLR (SEQ ID NO:3), to prevent damage caused by lymphocytes, NK cells or NK-like cells.~~

Claims 67-293 (Canceled)

Claim 294 (**New**): The method of claim 51, wherein the amino acid sequence of said polypeptide consists essentially of: AVL₄SAEKL₄R (SEQ ID NO:1).

Claim 295 (**New**): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide, wherein the amino acid sequence of said polypeptide consists essentially of: AVL₄SADKL₄N (SEQ ID NO:9), and said polypeptide is free of at least one component naturally

occurring with HSP47, wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.

Claim 296 (New): The method of claim 51, wherein the amino acid sequence recited in claims 51, 66, 294, and 295 is present in said polypeptide in multiple copies.

Claim 297 (New): The method of claim 296, wherein the amino acid sequence is present in two copies.

Claim 298 (New): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide, wherein the amino acid sequence of said polypeptide consists of: AVLSAX₄X₅LR (SEQ ID NO:1), wherein X₄ is D or E, X₅ is K or Q, and said polypeptide is free of at least one component naturally occurring with HSP47, wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.

Claim 299 (New): The method of claim 298, wherein the amino acid sequence of said polypeptide consists of: AVLSAEQLR (SEQ ID NO:3).

Claim 300 (New): The method of claim 298, wherein the amino acid sequence of said polypeptide consists of: AVLSAEKLR (SEQ ID NO:1).

Claim 302 (New): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide, wherein the amino acid sequence of said polypeptide consists of: AVLSADKLN (SEQ ID NO:9), and said polypeptide is free of at least one component naturally occurring with HSP47, wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.

Claim 303 (New): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide, wherein the amino acid sequence of said polypeptide consists of a plurality of copies of any of the amino acid sequences recited in claims 298-302, and said polypeptide is free of at least one

component naturally occurring with HSP47, wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.

Claim 304 (New): The method of claim 303, wherein the amino acid sequence is present in two copies.

Claim 305 (New): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a mammalian HSP47 that is free of at least one component naturally occurring with said HSP47, wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.

Claim 306 (New): The method of claim 305, wherein the mammalian HSP 47 is selected from the group consisting of human HSP47, mouse HSP47, rat HSP47, and hamster HSP47.

Claim 307 (New): The method of claim 306, wherein the mammalian HSP47 is the human HSP47 polypeptide sequence presented as SEQ ID NO:6.

Claim 308 (New): The method of claim 306, wherein the mammalian HSP47 is mouse HSP47.

Claim 309 (New): The method of claim 306, wherein the mammalian HSP47 is rat HSP47.

Claim 310 (New): The method of claim 306, wherein the mammalian HSP47 is hamster HSP47.

Claim 311 (New): A method for reducing or preventing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a chicken HSP47 that is free of at least one component naturally occurring with said HSP47, wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells, and said polypeptide prevents or reduces such damage.

Claim 312 (New): The method of any of claims 51, 295, 298, 302, 303, 305, or 311, wherein the polypeptide is synthesized or recombinantly expressed

Claim 313 (**New**): The method of any of claims 51, 66, 294-295, wherein the polypeptide has greater than 95% sequence identity to the human HSP47 polypeptide sequence presented as SEQ ID NO:6.